Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis

NCT04667988 is registered in ClinicalTrials.gov with Mansoura University as lead sponsor.

NCT NCT04667988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04667988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis
Lead sponsor
Mansoura University
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2019
Completion date
May 1, 2020
Enrollment
76 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

response assessment in newly diagnosed ra patients at 3rd month was evaluated by das28 and acr in relation to jak expression